Oracle Introduces Oracle Health Sciences Data Management Workbench
Bi-directional Integration with Oracle Health Sciences InForm Enables Real-time Clinical Trial Data Visibility and Reduces Data Management Costs
Oracle announced the release of the Oracle Health Sciences Data Management Workbench. The tool aims to allow researchers to "integrate, reconcile, and analyze clinical data faster and more accurately," automating the data load, transform and cleanse processes.
The solution integrates with Oracle Life Sciences Data Hub to automatically aggregate, integrate, and recincile the volume of trial data. By increasing data integration and standardizing data formats throughout the study process, Oracle Health Sciences Data Management Workbench also automates the identification and correction of discrepancies in multi-source data that can jeopardize the validity of a study. Oracle Health Sciences Data Management Workbench also integrates with Oracle Health Sciences InForm to enable automated, bi-directional and real-time information flow between the systems.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
